Activation of the adenylyl cyclase-cAMP-protein kinase A (PKA) intracellular signaling cascade is necessary for long-term memory consolidation in brain regions such as the hippocampus. However, the role of the PKA cascade in the working memory functions of the prefrontal cortex (PFC) is unknown. The present study examined the effects of manipulating PKA activity in the PFC using the cAMP stereoisomers Sp-cAMPS and Rp-cAMPS, which activate and inhibit PKA, respectively. Animals received bilateral infusions of Sp-cAMPS and/or RpcAMPS into the PFC immediately before testing on the delayed alternation task, a test of spatial working memory that depends on the integrity of the PFC. Low doses of Sp-cAMPS (0.21, 2.1, or 21 nmol/0.5 l) produced a marked, dose-dependent impairment in working memory performance. The impairment produced by infusion of Sp-cAMPS (21 nmol/0.5 l) was fully reversed by co-infusion of Rp-cAMPS (21 nmol/0.5 l), consistent with actions on PKA. Rp-cAMPS (21 or 42 nmol/0.5 l) by itself had no effect on performance. These results indicate that activation of the PKA intracellular signaling cascade in the PFC impairs working memory performance. The current findings contrast with studies of long-term memory consolidation, in which inhibition of PKA with agents such as Rp-cAMPS impaired memory consolidation (Bernabeu et al., 1997; Bourtchouladze et al., 1998) , whereas enhancement of the PKA pathway improved memory (Bernabeu et al., 1997; Barad et al., 1998 ). These results demonstrate that discrete cognitive processes subserved by different cortical regions are mediated by distinct intracellular mechanisms.
It is widely accepted that there are multiple types of memory processes subserved by interacting brain circuits. The hippocampal complex and related structures are important for the consolidation of long-term memories (Squire and Z ola-Morgan, 1991) , whereas the prefrontal cortex (PFC) is important for guiding behavior using working memories (Goldman-Rakic, 1987) , i.e., memories that must be constantly updated. There has been extensive analysis of the second messenger mechanisms underlying long-term memory consolidation, but little is known about the intracellular pathways underlying working memory processes. Consolidation of long-term memories involves the activation of several intracellular signals, including the cAM P-dependent protein kinase A (PK A) second messenger system. The PKA pathway appears to be particularly important for the later phases of memory consolidation that require protein synthesis; there is little change in memory immediately after training, but changes are evident several hours or days later. For example, genetic (Abel et al., 1997) or pharmacological (Bernabeu et al., 1997; Bourtchouladze et al., 1998) inhibition of PK A can disrupt hippocampal long-term potentiation (LTP) and hippocampus-based long-term memory, whereas activation of the cAM P-PKA pathway can enhance LTP and facilitate long-term memory (Bernabeu et al., 1997; Barad et al., 1998) . The current study provided the first examination of the functional consequences of PKA activation on the working memory functions of the PFC. Because long-term memory and working memory are often modulated by very different neurochemical mechanisms, e.g., high levels of catecholamines or stress exposure can improve long-term memory but impair working memory (for review, see Arnsten, 1998) , we hypothesized that the intracellular mechanisms governing working memory processes might also be fundamentally different from those subserving long-term memory changes. The present study examined the consequences of activating or inhibiting PKA in the rat PFC using two membrane-permeable stereoisomeric analogs of cAMP, Sp-cAMPS and Rp-cAMPS, which are commonly used to activate and inhibit PKA, respectively (Van Haastert et al., 1984; Surmeier et al., 1995; Punch et al., 1997; Bourtchouladze et al., 1998; Huang and Kandel, 1998; Self et al., 1998) . Working memory was assessed by a spatial delayed alternation task in a T maze, the cognitive task most commonly used to investigate PFC function in rodents (Larsen and Divac, 1978) .
The results from this study indicate that intracellular regulation in the PFC is opposite from the hippocampus, because activation of the PK A pathway impairs, rather than improves, the working memory f unctions of the PFC.
MATERIALS AND METHODS
The methods used in this study were the same as those used by Z ahrt et al. (1997) and Arnsten et al. (1999) . The reader is referred to these publications if more lengthy descriptions of methods are needed. The use of animals in this research was approved by the Yale Animal C are and Use Committee.
Subjects. Male Sprague Dawley rats weighing 240 -280 gm were purchased from C amm Research Institute (Wayne, NJ) or Taconic (Germantown, N Y) and pair-housed in filter frame cages. The rats were kept on a 12 hr light /dark cycle, and the experiments were conducted during the light phase. The animals were fed a diet of autoclaved Purina (St. L ouis, MO) rat chow (17 gm /d per rat) immediately after behavioral testing. Water was available ad libitum. Rats were weighed weekly and achieved weights of ϳ400 gm. Food rewards during cognitive testing were highly palatable miniature chocolate chips, thus minimizing the need for dietary regulation. Rats were assigned a single experimenter who handled them extensively before behavioral testing.
Delayed alternation. The delayed alternation task was selected for comparison to previous studies of (1) PFC catecholamine depletion (Bubser and Schmidt, 1990) , (2) stress (Murphy et al., 1996a) , and (3) intra-PFC D1 (Z ahrt et al., 1997) or ␣-1 adrenergic (Arnsten et al., 1999) agonist inf usions, which similarly used this paradigm. The delayed alternation task uses a number of processes associated with PFC f unction: (1) spatial working memory (Goldman-Rakic, 1987) , (2) egocentric spatial processing (Kesner et al., 1989) , and (3) inhibition of proactive interference and inappropriate motor responses (Mishkin, 1964; Kolb, 1990) and is thus a good task for detecting altered PFC f unction. Rats were initially habituated to a T maze (dimensions, 90 ϫ 65 cm) for 5 d until they were readily eating chocolate chips placed in the food wells at the end of each arm. After habituation, rats were trained on the delayed alternation task. On the first trial, animals were rewarded for entering either arm. Thereafter, for a total of 10 trials per session, rats were rewarded only if they entered the maze arm that was not previously chosen. Between trials the choice point was wiped with alcohol to remove any olfactory clues. The delay between trials was 0 sec during initial training and was raised in 5 sec intervals as needed to maintain performance at ϳ70 -80% correct. After approximately five training sessions, animals underwent surgery to implant indwelling guide cannulae directed at the PFC. Testing on the delayed alternation task was reinstated only after the implant had healed completely, ϳ2 weeks after surgery. Animals were adapted to the inf usion procedure, and inf usions were administered only when baseline performance was stable. Delays averaged 19.4 Ϯ 9.8 sec for the first inf usion and were gradually raised over the 6 month study to an average of 46.3 Ϯ 11.1 sec to maintain baseline performance at 70 -80% correct. This baseline level of performance allowed for the detection of either improvement or impairment with drug administration.
The response to drug was f urther characterized by analyzing the pattern of errors on the delayed alternation task. A perseverative pattern of response is consistent with dysf unction of the PFC (Kolb, 1990) . Perseverative responding was assessed by measuring the greatest number of consecutive entries into a single arm. Run times were measured to detect any changes in motor performance, and rats were observed for any gross changes in behavior.
Cannula implantation. After training on the delayed alternation task, rats underwent stereotaxic implantation of chronic guide cannulae. Surgery was performed under ketamine (80 mg / kg) and xylazine (10 mg / kg) anesthesia using aseptic methods. Guide cannulae consisted of 9.0 mm of 23 gauge stainless steel directed immediately dorsal to the medial PFC [prelimbic PFC; stereotaxic coordinates: anterioposterior, ϩ3.2 mm; mediolateral, Ϯ0.75 mm; dorsoventral (DV), Ϫ1.7 to Ϫ3.0 mm]. C annulae (Plastics Products) were affixed to the skull using dental cement secured with sterile stainless steel screws. A sterile stylet was screwed into place in each guide cannula to prevent occlusion. Stylets were changed on a regular basis to maintain patency.
Great care was taken to minimize pain and infection postoperatively to decrease stress to the animal. Rats were monitored on a daily basis for signs of distress or infection and were acutely treated with Buprenex (0.01 mg / kg) to decrease pain. Rats were housed singly after surgery.
Inf usion procedure. Animals were initially adapted to a mock inf usion protocol to minimize any stress associated with the procedure. Rats were gently restrained while the stylets were removed and replaced with 30 gauge sterile inf usion needles that extended to Ϫ4.5 mm DV below the skull. Bilateral inf usions were driven by a Harvard Apparatus (Holliston, M A) syringe pump set at a flow rate of 0.225 l /min using 25 l Hamilton syringes for an inf usion time of 2 min 13 sec. Needles remained in place for 2 min after the completion of the inf usion. Stylets were inserted back into the cannulae, and behavioral testing began immediately after the inf usion procedure. Drug treatment. The research used a within-subjects design; thus, all animals received all treatments within an experiment. Drug treatments were administered in a counterbalanced order with at least 1 week between each inf usion. In E xperiment 1, animals received four doses of Sp-cAM PS (0, 0.21, 2.1, or 21 nmol /0.5 l). In E xperiment 2, animals received four treatments: vehicle ϩ vehicle (0.5 l); vehicle ϩ SpcAM PS (lowest effective dose, 0.5 l); vehicle ϩ Rp-cAM PS (21 nmol, 0.5 l); or Sp-cAM PS ϩ Rp-cAM PS (21 nmol, 0.5 l). In E xperiment 3, a higher dose of Rp-cAM PS (42 nmol, 0.5 l) was compared with vehicle (0.5 l). The experimenter testing the animal was unaware of the drug treatment conditions. Sp-cAM PS and Rp-cAM PS were purchased from Research Biochemicals (Natick, M A). Sp-cAM PS and Rp-cAM PS were dissolved in sterile PBS as described by Punch et al. (1997) . For example, the 21 nmol dosage was produced by dissolving 1 mg of Sp-cAM PS or Rp-cAM PS in 54 l of PBS to produce a 42 mM concentration; 0.5 l of this solution was inf used into each side of the PFC.
Histolog y. At the completion of the experiment, rats were killed by overdose with barbiturate. Dye was inf used into the cannulae before death in a subset of animals to aid visualization of cannula placement. Brains were stored in formalin, sectioned, and analyzed for histological verification of cannulae placement. All rats had correctly placed cannulae. The location of the ventral tips of the guide cannula are illustrated in Figure 1 .
Data anal ysis. Given within-subjects comparisons, data were analyzed with repeated measures designs. In E xperiment 1, the effects of increasing dose of Sp-cAM PS were evaluated using a one-way repeated measures ANOVA with planned comparisons (test of effects; Systat, Evanston, IL). In E xperiment 2, the effects of Rp-cAM PS co-inf usion on the Sp-cAM PS response were evaluated using a two-way repeated analysis (2-ANOVA-R) with planned comparisons (user-defined contrasts; Systat). Paired comparisons in E xperiment 3 were evaluated using a paired t test, T-dependent (T-dep). Statistical analyses were performed on a Macintosh G3 computer using Systat software.
RESULTS

Experiment 1: effects of intra-PFC infusions of SpcAMPS on delayed alternation performance
The first experiment (n ϭ 7) examined the effects of activating PKA on delayed alternation performance by infusing Sp-cAMPS (0, 0.21, 2.1, or 21 nmol/0.5 l) into each side of the PFC. The results are shown in Figure 2 A. Sp-cAMPS produced a marked, dose-related impairment in delayed alternation performance (one way ANOVA with repeated measures, significant effect of Sp-cAMPS dose: F (3,18) ϭ 11.49; p ϭ 0.00019). Only the 21 nmol dose was significantly different from vehicle (user-defined contrasts: vehicle vs 0.21 nmol, F (1,6) ϭ 0.48; p ϭ 0.52; vehicle vs 2.1 nmol, F (1,6) ϭ 1.24; p ϭ 0.31; vehicle vs 21nmol, F (1,6) ϭ 140.245; p ϭ 0.00002). Consistent with PFC dysfunction, 21 nmol SpcAMPS infusions tended to produce a more perseverative pattern of responding (greatest number of consecutive entries into an arm after vehicle vs 21 nmol Sp-cAMPS infusions. 2.8 Ϯ 0.4 vs 4.4 Ϯ 1.0 entries; T-dep ϭ 2.67; df ϭ 4; p ϭ 0.056). Rats infused with 21 nmol Sp-cAMPS also tended to freeze and have slower response times, although this effect was highly variable (response times after vehicle vs 21nmol Sp-cAMPS infusions, 4.4 Ϯ 1.1 vs 19.5 Ϯ 10.1 sec; T-dep ϭ 1.6; df ϭ 4; p ϭ 0.18) and not correlated with accuracy of response ( p ϭ 0.3). Performance returned to normal levels of responding the following testing day (70.0 Ϯ 11.2% correct).
A pilot experiment in two animals with more superficially placed guide cannula (DV, Ϫ1.7 mm) showed that shallow infusions of 21 nmol /0.5 l Sp-cAM PS into the shoulder cortex dorsal to the PFC had no effect on delayed alternation performance (90% correct), whereas the deeper inf usions into the PFC were effective in impairing performance (40% correct). Further control inf usions into brain areas dorsal, lateral, and ventral to the PFC will be needed to verif y anatomical specificity of the SpcAMPS response.
Experiment 2: Rp-cAMPS reversal of the Sp-cAMPS response
To test whether the detrimental effects of Sp-cAM PS resulted from actions on PK A, the Sp-cAM PS response was challenged with co-inf usion of Rp-cAM PS, the isomer that inhibits PKA activity. Animals (n ϭ 5) were administered four different treatments in counterbalanced order: vehicle, Sp-cAM PS (lowest effective dose for each rat; see legend to Fig. 2 B) , 21 nmol of Rp-cAM PS, and Sp-cAM PS plus 21 nmol of Rp-cAMPS. The results of this experiment can be seen in Figure 2 
Experiment 3: effects of a higher dose of Rp-cAMPS on delayed alternation performance
It is possible that the 21 nmol dose of Rp-cAMPS had no effect on performance by itself because of insufficient dosage. This hypothesis was tested by infusing a higher dose of Rp-cAMPS (42 nmol/0.5 l) into the PFC. The 42 nmol dose has previously been shown to inhibit PKA activity and signs of opioid withdrawal when infused into the nucleus locus coeruleus of opiate-addicted rats (Punch et al., 1997) and to reduce cocaine self-administration when infused into the nucleus accumbens (Self et al., 1998) . The results of the current experiment can be seen in Figure 2C . The 42 nmol dose of Rp-cAMPS had no effect on delayed alternation performance compared with vehicle control infusions (vehicle, 74 Ϯ 5.7% correct; 42 nmol Rp, 72 Ϯ 7.4%; n ϭ 5; T-dep, p Ͼ 0.8).
DISCUSSION
The present study revealed that infusions of the PKA activator Sp-cAMPS into the rodent PFC markedly impaired performance of the delayed alternation task. It is noteworthy that performance Results represent mean Ϯ SEM percent correct; n ϭ 7. *Significantly different from performance after vehicle inf usion. B, The detrimental effects of Sp-cAM PS were reversed by co-inf usion of Rp-cAMPS (21 nmol /0.5 l). The dose of Sp-cAM PS was the lowest dose that substantially impaired performance (n ϭ 3, 21 nmol; n ϭ 1, 2.1 nmol; n ϭ 1, 0.21 nmol). Rp-cAM PS (21 nmol /0.5 l) had no effect on performance by itself. Results represent mean Ϯ SEM percent correct; n ϭ 5. *Significantly different from performance after vehicle inf usion; **significantly different from performance after Sp-cAM PS inf usion. VEH, vehicle; Sp, Sp-cAM PS; Rp, Rp-cAM PS. C, Intra-PFC inf usions of Rp-cAMPS (42 nmol /0.5 l) had no effect on delayed alternation performance. Results represent mean Ϯ SEM percent correct; n ϭ 5.
after 21 nmol Sp-cAM PS treatment produced near chance levels of response for a two-choice task (ϳ40% correct), and that this effect was comparable in magnitude with the effects of acute ablation of the PFC (Brito et al., 1982) . The impairment induced by Sp-cAM PS was reversed by the PK A inhibitor Rp-cAMPS (21nmol). Importantly, neither dose of Rp-cAM PS (21 or 42 nmol) altered performance on its own. Thus, the reversal of the Sp-cAM PS response could not result from additive effects of the two treatments. This response profile also suggests that the impairment observed after Sp-cAM PS treatment did not result from nonspecific disruption of the PK A cascade, because Rp-cAMPS would have been equally disruptive if this were true. The data also argue against actions at adenosine receptors or cAMP-gated channels, which can be stimulated by adenosine compounds such as Sp-cAM PS and Rp-cAM PS (Finn et al., 1996) . However, Spand Rp-cAM PS would be expected to have similar effects on behavior if they were acting through these mechanisms (Finn et al., 1996) . Rather, the current results are consistent with competing effects of Sp-cAM PS versus Rp-cAM PS on PK A activity. More research is needed with additional agents that increase activity of the cAM P-PK A pathway to reinforce this interpretation.
There are several possible explanations for the lack of effect of Rp-cAM PS by itself on delayed alternation performance. One unlikely possibility is that Rp-cAM PS may not have penetrated the cells in the PFC sufficiently to inhibit PK A activity. However, the 42 nmol dose has been effective in other brain regions (Punch et al., 1997; Self et al., 1998) , and the 21 nmol dose was fully effective in reversing the Sp-cAM PS response in the present study. These data indicate that Rp-cAM PS was capable of permeating the cell membrane and inhibiting PK A activity in this study. Alternatively, the PK A cascade may not be sufficiently active in PFC under nonstress conditions to visibly influence behavior, or the Rp-cAM PS doses used in the current study, although effective in other brain regions, may not have been appropriate for altering PFC f unction. More research is needed with a wider Rp-cAM PS dose range and with additional agents to thoroughly examine the consequences of PK A inhibition on PFC function. We are currently conducting an extensive study testing a wide range of . To date, our preliminary results have shown no effect on performance with these additional doses.
Possible relevance of PKA activation to stress-induced PFC dysfunction
Activation of the PK A pathway may contribute to the deficits in PFC f unction observed during exposure to mild, uncontrollable stress. E xposure to stress impairs performance of spatial working memory tasks such as delayed alternation and delayed response in rats and monkeys, respectively (Murphy et al., 1996a; Arnsten and Goldman-Rakic, 1998) . In contrast, stress has no effect on control tasks such as spatial or visual pattern discrimination that have similar motor and motivational demands but do not depend on PFC f unction (Murphy et al., 1996a; Arnsten and GoldmanRakic, 1998) . This pattern of results has indicated that stress does not produce nonspecific performance deficits but rather impairs the cognitive f unctions of the PFC. Stress-induced cognitive deficits arise, at least in part, from high levels of dopamine D1 receptor stimulation in the PFC (Murphy et al., 1996a; Arnsten and Goldman-Rakic, 1998 ), a receptor family that is positively coupled to the PK A pathway (Duman and Nestler, 1995) . Exposure to mild stress (Murphy et al., 1996a) or intra-PFC infusions of either a D1 receptor agonist (Zahrt et al., 1997) or Sp-cAMPS (present study) impair delayed alternation performance and produced a mildly perseverative pattern of response. D1 receptor stimulation has also been shown to decrease working memory at the cellular level as measured by delay-related activity of PFC pyramidal neurons (Williams and Goldman-Rakic, 1995) . High levels of D1 receptor stimulation in the PFC may impair working memory by diminishing the calcium currents that convey signals from the distal dendrites to the soma (Yang and Seamans, 1996; Zahrt et al., 1997) . This process is likely mediated by activation of PKA (Surmeier et al., 1995) . Conversely, ␣-2 adrenergic agonists can inhibit the cAMP-PKA pathway via G i , and these agents are very effective in reversing stress-induced cognitive deficits (Birnbaum and Arnsten, 1996; Murphy et al., 1996b; Arnsten and Goldman-Rakic, 1998) . Although previous studies have focused on ␣-2 agonist reduction of catecholamine release (Murphy et al., 1996b) , the present data suggest that ␣-2 agonists may also protect PFC cognitive functions by inhibiting activation of the PKA pathway. More research is needed to determine whether intra-PFC infusions of specific PKA inhibitors can prevent stressinduced working memory deficits. Additional research is also needed to observe whether PKA activation in the PFC, like exposure to stress, is without effect on performance of control tasks. It also will be of interest to perform biochemical studies to examine whether stress exposure activates the cAMP-PKA pathway in the PFC. However, given the inherently stressful nature of many biochemical experiments, it may require considerable effort to maintain nonstressed control subjects.
Comparisons with PKA mediation of long-term memory consolidation
The present results contrast with an extensive literature demonstrating that activation of the PKA pathway is critical for the establishment of long-term memory consolidation, particularly processes dependent on protein synthesis. Much of this work has focused on hippocampal and amygdala function, in which both electrophysiological and behavioral studies indicate that PKA activation enhances long-term memory consolidation (Abel et al., 1997; Bernabeu et al., 1997; Barad et al., 1998; , Huang et al., 1998 . Activation of the PKA pathway appears important for learning and memory consolidation across many species, including Drosophila (Yin et al., 1994) , Aplysia (Dash et al., 1990) , and crab Chasmagnathus (Romano et al., 1996) , as well as rodents (Frey et al., 1993; Bourtchouladze et al., 1994; Weisskopf et al., 1994) . Thus, it is striking to observe opposite effects of activating PKA on working memory function in the current study. However, if one considers that working memory requires the continuous updating of memory buffers, whereas long-term memory consolidation involves static changes, these opposite effects should not be unexpected. Given the importance of intracellular signaling mechanisms to long-term memory consolidation, pharmaceutical companies are developing agents that enhance the activity of PKA and related pathways as potential cognitive enhancers for human memory disorders. The results from the current study caution that mechanisms leading to "cognitive enhancement" are not universal. Thus, efforts to produce agents that would activate the PKA pathway might enhance long-term memory consolidation but might impair the ability to use working memory to flexibly and effectively guide behavior.
